283 related articles for article (PubMed ID: 28284178)
1. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.
Sezer A; Celik M; Yilmaz Bulbul B; Can N; Tastekin E; Ayturk S; Ustun F; Guldiken S; Sut N
Bosn J Basic Med Sci; 2017 May; 17(2):144-151. PubMed ID: 28284178
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
4. Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis.
Al Afif A; Williams BA; Rigby MH; Bullock MJ; Taylor SM; Trites J; Hart RD
Thyroid; 2015 Sep; 25(9):1008-12. PubMed ID: 26161997
[TBL] [Abstract][Full Text] [Related]
5. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma.
Park JS; Chang JW; Liu L; Jung SN; Koo BS
Oral Oncol; 2017 Sep; 72():183-187. PubMed ID: 28222967
[TBL] [Abstract][Full Text] [Related]
7. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
8. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
9. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.
Zheng X; Xia T; Lin L; Gao S; Lee Y; Yu Y; Wei S; Gao M
World J Surg Oncol; 2012 Jun; 10():104. PubMed ID: 22681706
[TBL] [Abstract][Full Text] [Related]
10. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
[TBL] [Abstract][Full Text] [Related]
11. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
12. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
13. Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis.
Beom Heo D; Piao Y; Hee Lee J; Ju SH; Yi HS; Su Kim M; Won HR; Won Chang J; Seok Koo B; Eun Kang Y
Oral Oncol; 2022 Nov; 134():106115. PubMed ID: 36108524
[TBL] [Abstract][Full Text] [Related]
14. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
15. Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer.
Park HS; Jung CK; Lee SH; Chae BJ; Lim DJ; Park WC; Song BJ; Kim JS; Jung SS; Bae JS
Cancer Sci; 2012 Feb; 103(2):305-9. PubMed ID: 22118425
[TBL] [Abstract][Full Text] [Related]
16. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
17. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
18. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer.
Tam AA; Özdemir D; Çuhacı N; Başer H; Aydın C; Yazgan AK; Ersoy R; Çakır B
Endocrine; 2016 Sep; 53(3):774-83. PubMed ID: 27090526
[TBL] [Abstract][Full Text] [Related]
19. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
Walts AE; Mirocha JM; Bose S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
[TBL] [Abstract][Full Text] [Related]
20. An Evaluation of Clinicopathological Factors Effective in the Development of Central and Lateral Lymph Node Metastasis in Papillary Thyroid Cancer.
Aydin Buyruk B; Kebapci N; Yorulmaz G; Buyruk A; Kebapci M
J Natl Med Assoc; 2018 Aug; 110(4):384-390. PubMed ID: 30126565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
